Effective gene therapy with nonintegrating lentiviral vectors
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Retroviral and lentiviral vector integration into host-cell chromosomes carries with it a finite chance of causing insertional mutagenesis. This risk has been highlighted by the induction of malignancy in mouse models, and development of lymphoproliferative disease in three individuals with severe combined immunodeficiency-X1 (refs. 2,3). Therefore, a key challenge for clinical therapies based on retroviral vectors is to achieve stable transgene expression while minimizing insertional mutagenesis. Recent in vitro studies have shown that integration-deficient lentiviral vectors can mediate stable transduction. With similar vectors, we now show efficient and sustained transgene expression in vivo in rodent ocular and brain tissues. We also show substantial rescue of clinically relevant rodent models of retinal degeneration. Therefore, the high efficiency of gene transfer and expression mediated by lentiviruses can be harnessed in vivo without a requirement for vector integration. For therapeutic application to postmitotic tissues, this system substantially reduces the risk of insertional mutagenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NILVs encoding for in vivo expression of GFP have been reported in organs such as the brain, liver, and spinal cord via stable gene transfer for longer periods (up to months) in several studies [22,73,131,132,133,134].”
From Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through (2022) · cites this paper as [22]
In the citing paper
“A non-integrating LV was engineered to avoid unwanted integration. In these vectors, selected mutations were induced within the integrase coding region to eliminate the integrase activities without affecting reverse transcription and transport of the pre-integrating complex into the nucleus [48,49,50].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [49]
Citations
Cites
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903 · cited 1×
“Class I integration-deficient lentiviral vectors have been reported to be inefficient for transduction of dividing cells in vitro”
BackgroundLMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Self-citationA Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341 · cited 1×
“We produced paired integration-proficient and integration-deficient HIV-1 vectors using self-inactivating system”
MethodNaldini, L., Blömer, U., Gage, F. H., Trono, D., & Verma, I. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11382 · Cited by 1,499 · cited 1×
“In contrast, direct administration of nonintegrating vectors based on human immunodeficiency virus (HIV) or feline immunodeficiency virus (FIV) has not previously resulted in significant expression in vivo”
BackgroundA quantitative assay for HIV DNA integration in vivo
Butler, S. L., Hansen, M. S. T., & Bushman, F. D. (2001) · Nature Medicine · doi:10.1038/87979 · Cited by 687 · cited 1×
“We carried out qPCR titrations of total vector DNA according to a published protocol for late reverse transcriptase amplicon quantificatio”
MethodMurine leukemia induced by retroviral gene marking
Li, Z., Düllmann, J., Schiedlmeier, B., Schmidt, M., von Kalle, C., Meyer, J., Forster, M., Stocking, C., Wahlers, A., Frank, O., et al. (2002) · Science · doi:10.1126/science.1068893 · Cited by 525 · cited 1×
“We designed three different LAM-PCR reactions to scan vector regions downstream of the 5¢-dLTR (1), upstream of the 3¢-dLTR (2) and downstream of residual env sequences (a region including cPPT/CTS and internal promoter, 3) for integration junctions.”
MethodSelf-citationDemaison, C., Parsley, K., Brouns, G., Scherr, M., Battmer, K., Kinnon, C., Grez, M., & Thrasher, A. J. (2002) · Human Gene Therapy · doi:10.1089/10430340252898984 · Cited by 486
Self-citationSide effects of retroviral gene transfer into hematopoietic stem cells
Baum, C., Düllmann, J., Li, Z., Fehse, B., Meyer, J., Williams, D. A., & von Kalle, C. (2003) · Blood · doi:10.1182/blood-2002-07-2314 · Cited by 435
Case, S. S., Price, M. A., Jordan, C. T., Yu, X. J., Wang, L., Bauer, G., Haas, D. L., Xu, D., Stripecke, R., Naldini, L., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.2988 · Cited by 386
Shank, P. R., Hughes, S. H., Kung, H.-J., Majors, J. E., Quintrell, N., Guntaka, R. V., Bishop, J. M., & Varmus, H. E. (1978) · Cell · doi:10.1016/0092-8674(78)90063-6 · Cited by 383
Cited by
Items 101–200 of 459
Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through
Gurumoorthy, N., Nordin, F., Tye, G. J., Wan Kamarul Zaman, W. S., & Ng, M. H. (2022) · Biomedicines · doi:10.3390/biomedicines10010107 · Cited by 69
Izmiryan, A., Ganier, C., Bovolenta, M., Schmitt, A., Mavilio, F., & Hovnanian, A. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.06.008 · Cited by 68
Use of HIV as a gene transfer vector.
Pluta, K. D., & Kacprzak, M. M. (2009) · Acta Biochimica Polonica · doi:10.18388/abp.2009_2490 · Cited by 89
“Moreover, the Lentivirus-based episomal system for gene delivery proved its usefulness in the genetic correction of the disorder in animal models (Yáñez-Muñoz et al., 2006), effective vaccination (see references in section on Lentiviral vectors in clinical gene therapy applications), gene silencing mediated by RNA int…”
MethodNovel lentiviral vectors with mutated reverse transcriptase for mRNA delivery of TALE nucleases
Mock, U., Riecken, K., Berdien, B., Qasim, W., Chan, E., Cathomen, T., & Fehse, B. (2014) · Scientific Reports · doi:10.1038/srep06409 · Cited by 69
Gene Therapy in Inherited Retinal Diseases: An Update on Current State of the Art
Amato, A., Arrigo, A., Aragona, E., Manitto, M. P., Saladino, A., Bandello, F., & Battaglia Parodi, M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.750586 · Cited by 67
“GUCY2D Guanylate cyclase-1 Phototransduction ∼120 (18)”
MethodMechanism of Reduction in Titers From Lentivirus Vectors Carrying Large Inserts in the 3′LTR
Urbinati, F., Arumugam, P. I., Higashimoto, T., Perumbeti, A., Mitts, K., Xia, P., & Malik, P. (2009) · Molecular Therapy · doi:10.1038/mt.2009.89 · Cited by 70
Gene Correction of a Duchenne Muscular Dystrophy Mutation by Meganuclease-Enhanced Exon Knock-In
Popplewell, L. J., Koo, T., Leclerc, X., Duclert, A., Mamchaoui, K., Gouble, A., Mouly, V., Voït, T., Pâques, F., Cédrone, F., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.081 · Cited by 73
Self-citationCRISPR/Cas9 Epigenome Editing Potential for Rare Imprinting Diseases: A Review
Syding, L. A., Nickl, P., Kašpárek, P., & Sedláček, R. (2020) · Cells · doi:10.3390/cells9040993 · Cited by 74
“Although lentiviral or retroviral delivery systems are capable of carrying large transgenic cassettes, their immunogenicity, the potential to competent other viruses, and tendency to randomly integrate into the host genome make these systems less convenient for these types of therapeutic applications, even though atte…”
BackgroundBenabdallah, B., Allard, E., Yao, S., Friedman, G., Gregory, P. D., Eliopoulos, N., Fradette, J., Spees, J. L., Haddad, É., Holmes, M. C., et al. (2010) · Cytotherapy · doi:10.3109/14653240903583803 · Cited by 64
Design and potential of non-integrating lentiviral vectors
Shaw, A., & Cornetta, K. (2014) · Biomedicines · doi:10.3390/biomedicines2010014 · Cited by 60
“D64V Stable gene transfer to retina and brain VSV-G CMV & SFFV Green Fluorescence Protein Ocular & Brain Tissue [89]”
BackgroundMethodInfluentialLDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives
Al-Allaf, F. A., Coutelle, C., Waddington, S. N., David, A. L., Harbottle, R. P., & Themis, M. (2010) · International Archives of Medicine · doi:10.1186/1755-7682-3-36 · Cited by 70
“Recent studies using IDLVs have demonstrated effective gene transfer in the eye [176], brain [174,179], muscle [180], and to a lesser extent in the liver [181], albeit at lower expression levels than with integrating vectors.”
BackgroundCollin, J., & Lako, M. (2011) · Stem Cells · doi:10.1002/stem.658 · Cited by 62
The old and the new: Prospects for non-integrating lentiviral vector technology
Apolonia, L. (2020) · Viruses · doi:10.3390/v12101103 · Cited by 58
“Taking these observations together, Yanez-Munoz and colleagues tested lentiviral vectors that did not integrate their genome into host chromosomes and clearly demonstrated that these vectors maintained full capacity for transgene expression in target cells both in vitro and in vivo [37].”
BackgroundGene supplementation therapy for recessive forms of inherited retinal dystrophies
Smith, A. J., Bainbridge, J. W., & Ali, R. R. (2011) · Gene Therapy · doi:10.1038/gt.2011.161 · Cited by 66
Self-citationPelascini, L. P. L., Janssen, J. M., & Gonçalves, M. A. F. V. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.069 · Cited by 57
“, 2006), brain (Philippe et al., 2006; Yáñez-Muñoz et al., 2006), skeletal muscle (Apolonia et al.”
BackgroundInfluentialRetinal Ganglion Cell Gene Therapy and Visual System Repair
Hellström, M., & Harvey, A. R. (2011) · Current Gene Therapy · doi:10.2174/156652311794940746 · Cited by 60
“Furthermore, the demonstration of efficient in vivo transduction with an integrase-deficient HIV-1 vector suggests potentially safer application to human gene therapy using modified LV vectors [32].”
MethodKantor, B., Bayer, M., Ma, H., Samulski, J., Li, C., McCown, T., & Kafri, T. (2011) · Molecular Therapy · doi:10.1038/mt.2010.277 · Cited by 56
Herzog, R. W. (2015) · Frontiers in Bioscience · doi:10.2741/4324 · Cited by 55
Gene therapy and peripheral nerve repair: a perspective
Hoyng, S. A., de Winter, F., Tannemaat, M. R., Blits, B., Malessy, M. J. A., & Verhaagen, J. (2015) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2015.00032 · Cited by 58
Hellström, M., Pollett, M. A., & Harvey, A. R. (2011) · Journal of Neurotrauma · doi:10.1089/neu.2011.1928 · Cited by 55
Lentiviral Vector Integration Profiles Differ in Rodent Postmitotic Tissues
Bartholomae, C. C., Arens, A., Balaggan, K. S., Yáñez‐Muñoz, R. J., Montini, E., Howe, S. J., Paruzynski, A., Korn, B., Appelt, J. U., MacNeil, A., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.19 · Cited by 60
Self-citationTrittibach, P. C., Barker, S. E., Broderick, C. A., Natkunarajah, M., Durán, Y., Robbie, S. J., Bainbridge, J. W., Smith, A. J., Sarra, G., Dick, A. D., et al. (2008) · Gene Therapy · doi:10.1038/gt.2008.109 · Cited by 54
Self-citationYi, G., Choi, J. G., Bharaj, P., Abraham, S., Dang, Y., Kafri, T., Alozie, O., Manjunath, M. N., & Shankar, P. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.52 · Cited by 52
Askou, A. L., Aagaard, L., Kostic, C., Arsenijevic, Y., Hollensen, A. K., Bek, T., Jensen, T. G., Mikkelsen, J. G., & Corydon, T. J. (2015) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.64 · Cited by 52
Retroviral and Lentiviral Vectors for the Induction of Immunological Tolerance
Dufait, I., Liechtenstein, T., Lanna, A., Bricogne, C., Laranga, R., Padella, A., Breckpot, K., & Escors, D. (2012) · Scientifica · doi:10.6064/2012/694137 · Cited by 65
“NILVs have been shown to be effective for gene modi�cation of retina, muscle, and brain [135] [136] [137] [138] , and they have been already used for vaccination [108, 118, 139, 140] .”
Rittiner, J. E., Moncalvo, M., Chiba‐Falek, O., & Kantor, B. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00148 · Cited by 62
“For example, we demonstrated that the deletion of negative transcription elements (NTE) located within U3-region of the 3LTR resulted in significant activation of IDLV expression in both in vitro and in vivo experiments (Philippe et al., 2006; Yáñez-Muñoz et al., 2006; Kantor et al., 2011).”
BackgroundGene Therapy of Inherited Retinopathies: A Long and Successful Road from Viral Vectors to Patients
Colella, P., & Auricchio, A. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.123 · Cited by 50
“, 2012), the issue of insertional mutagenesis is being addressed through the generation of nonintegrating LVs (Yanez-Munoz et al., 2006), whereas vector replication and mobilization are being tackled through the use of nonprimate LVs (Pauwels et al.”
BackgroundSumiyoshi, T., Holt, N. G., Hollis, R. P., Ge, S., Cannon, P. M., Crooks, G. M., & Kohn, D. B. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.109 · Cited by 55
“Other delivery methods for SB plasmids such as hydrodynamic injection, lipofection, and cationic polymer polyethyleneimine (PEI) have also been actively investigated (Yant et al. , 2000; Bell et al. , 2007; Belur et al. , 2007; Liu et al. , 2009).”
InfluentialDurable, Safe, Multi-gene Lentiviral Vector Expression in Feline Trabecular Meshwork
Khare, P. D., Loewen, N. A., Teo, W., Barraza, R., Saenz, D. T., Johnson, D. H., & Poeschla, E. M. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300318 · Cited by 50
Lentiviral vectors for ocular gene therapy
Arsenijevic, Y., Berger, A., Udry, F., & Kostic, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081605 · Cited by 47
“Additionally, the use of integrative-deficient LV (IDLV) can also be an efficient alternative for non-dividing cells [51,52].”
Cancer gene therapy goes viral: viral vector platforms come of age
Bezeljak, U. (2022) · Radiology and Oncology · doi:10.2478/raon-2022-0002 · Cited by 51
Retroviral Vectors: Post Entry Events and Genomic Alterations
Nowrouzi, A., Glimm, H., Kalle, C. V., & Schmidt, M. (2011) · Viruses · doi:10.3390/v3050429 · Cited by 51
“retinal degeneration in a well-established rodent model for ocular gene therapy was reported under the use of an integrase-deficient HIV-1 vector without apparent side effects [142].”
BackgroundSelf-citationHistones Are Rapidly Loaded onto Unintegrated Retroviral DNAs Soon after Nuclear Entry
Wang, G. Z., Wang, Y., & Goff, S. P. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.10.009 · Cited by 47
“Since the DNAs are not stably integrated, their use is limited to settings where transient expression is sufficient for a therapeutic outcome (Negri et al., 2010; Yanez-Munoz et al., 2006).”
Development and use of SIV-based Integrase defective lentiviral vector for immunization
Michelini, Z., Negri, D. R. M., Baroncelli, S., Spada, M., Leone, P., Bona, R., Klotman, M. E., & Cara, A. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.05.070 · Cited by 47
Optimizing gene delivery vectors for the treatment of heart disease
Gray, S. J., & Samulski, R. J. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.7.911 · Cited by 53
“(2008) 8(7) high levels of transgene expression for up to one year in the rodent eye and brain [81] .”
BackgroundNovel therapies for epilepsy in the pipeline
Mesraoua, B., Deleu, D., Kullmann, D. M., Shetty, A. K., Boon, P., Perucca, E., Mikati, M. A., & Asadi‐Pooya, A. A. (2019) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2019.04.042 · Cited by 54
“It is, furthermore, possible to reduce the risk of insertional mutagenesis by using an integrationincompetent variant [15].”
BackgroundHu, B., Dai, B., & Wang, P. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.08.012 · Cited by 45
“To date, several reports have firmly established the utility of IDLVs for mediating gene delivery with high efficacy to a range of post-mitotic tissues [20-23] and for inducing antigen-specific immune responses upon in vivo immunization [24-27].”
BackgroundSundarasetty, B. S., Chan, L., Darling, D., Giunti, G., Farzaneh, F., Schenck, F., Naundorf, S., Kuehlcke, K., Ruggiero, E., Schmidt, M., et al. (2015) · Gene Therapy · doi:10.1038/gt.2015.43 · Cited by 47
Self-citationSuwanmanee, T., Hu, G., Gui, T., Bartholomae, C. C., Kutschera, I., von Kalle, C., Schmidt, M., Monahan, P. E., & Kafri, T. (2014) · Molecular Therapy · doi:10.1038/mt.2013.188 · Cited by 44
Self-citationDelivery of CRISPR-Cas9 system for screening and editing RNA binding proteins in cancer
Yan, J., Kang, D. D., Turnbull, G., & Dong, Y. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114042 · Cited by 46
Nonviral ocular gene therapy: assessment and future directions.
Conley, S. M., Cai, X., & Naash, M. I. (2008) · PubMed · Cited by 52
Genomic insertion of lentiviral DNA circles directed by the yeast Flp recombinase
Moldt, B., Staunstrup, N. H., Jakobsen, M., Yáñez-Muñoz, R. J., & Mikkelsen, J. G. (2008) · BMC Biotechnology · doi:10.1186/1472-6750-8-60 · Cited by 44
“However, integration-defective lentiviral (IDLV) vectors carrying an inactive integrase protein that abolish the normal viral integration pathway have recently emerged as novel efficient gene carriers, facilitating high levels of transient expression from linear and circular DNA forms [6-9].”
BackgroundMethodSelf-citationBarriers for retinal gene therapy: separating fact from fiction.
Kumar-Singh, R. (2008) · Vision Research · doi:10.1016/j.visres.2008.05.005 · Cited by 43
“The objective is not to claim that Ad is superior to AAV or Lv but rather to highlight recent developments in Ad vector technology and its application in ocular tissues that warrant further consideration.”
BackgroundRomano, G. (2012) · ISRN Oncology · doi:10.5402/2012/616310 · Cited by 41
“Studies on mouse models focused on in vivo gene delivery of episomal lentiviral vectors in the central nervous system [128], stem cells of the hematopoietic compartment [130], muscles [131], and ocular tissues [135].”
BackgroundTargeted gene therapies: tools, applications, optimization
Humbert, O., Davis, L., & Maizels, N. (2012) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2012.658112 · Cited by 50
Genetic manipulation for inherited neurodegenerative diseases: myth or reality?
Yu‐Wai‐Man, P. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-308329 · Cited by 45
Development of Viral Vectors for Use in Cardiovascular Gene Therapy
Williams, P. D., Ranjzad, P., Kakar, S. J., & Kingston, P. A. (2010) · Viruses · doi:10.3390/v2020334 · Cited by 51
“Sustained transgene expression with non-integrating lentivirus has been demonstrated in vivo in the rodent brain [115], retina [116], skeletal muscle [117] and liver [118].”
BackgroundHigh Transgene Expression by Lentiviral Vectors Causes Maldevelopment of Purkinje Cells In Vivo
Sawada, Y., Kajiwara, G., Iizuka, A., Takayama, K., Shuvaev, А. N., Koyama, C., & Hirai, H. (2010) · The Cerebellum · doi:10.1007/s12311-010-0161-1 · Cited by 42
“happen, potential defects can be removed by using recently developed lentiviral vectors with almost no-integrating capability to host chromosomes [17, 29].”
BackgroundWolff, J. H., & Mikkelsen, J. G. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00865-4 · Cited by 47
“(IDLVs) produced with packaging constructs carrying the D64V variation were originally shown to facilitate effective gene transfer and stable expression in postmitotic tissues in vivo [155] and have been adapted for delivery of alternative integration platforms based on the transient expression of recombinases [156] a…”
BackgroundRubanyi, G. M. (2013) · Molecular Therapy · doi:10.1038/mt.2013.13 · Cited by 43
Efficient gene targeting mediated by a lentiviral vector-associated meganuclease
Izmiryan, A., Basmaciogullari, S., Henry, A., Pâques, F., & Danos, O. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr524 · Cited by 46
Hauswirth, W. W., Alemán, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hgt.2008.107 · Cited by 47
Gene Therapy of ABCA4-Associated Diseases
Auricchio, A., Trapani, I., & Allikmets, R. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017301 · Cited by 41
Efficient gene expression from integration-deficient lentiviral vectors in the spinal cord
Peluffo, H., Foster, E., Ahmed, S. G., Lago, N., Hutson, T. H., Moon, L., Yip, P., Wanisch, K., Caraballo-Miralles, V, Olmos, G., et al. (2013) · Gene Therapy · doi:10.1038/gt.2012.78 · Cited by 40
Self-citationLentiviral Vectors for Cancer Immunotherapy and Clinical Applications
Liechtenstein, T., Pérez‐Janices, N., & Escors, D. (2013) · Cancers · doi:10.3390/cancers5030815 · Cited by 52
“Cells can be targeted with these vectors and lead to prolongued transgene expression as long as the target cells do not divide after transduction [53,110].”
BackgroundNon‐viral retinal gene therapy: a review
Issa, P. C., & MacLaren, R. E. (2012) · Clinical & Experimental Ophthalmology · doi:10.1111/j.1442-9071.2011.02649.x · Cited by 39
“Strategies to obviate these concerns are being developed.(20) However, in parallel with improving viral delivery systems, these challenges highlight the need to develop non-viral alternatives.”
BackgroundSelf-citationBoza-Moran, M.-G., Martínez‐Hernández, R., Bernal, S., Wanisch, K., Also‐Rallo, E., Heron, A. L., Alías, L., Denis, C., Girard, M., Yee, J., et al. (2015) · Scientific Reports · doi:10.1038/srep11696 · Cited by 44
Self-citationAdvancements in reprogramming strategies for the generation of induced pluripotent stem cells
Lai, M. I., Wendy-Yeo, W. Y., Ramasamy, R., Nordin, N., Rosli, R., Veerakumarasivam, A., & Abdullah, S. (2011) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-011-9552-6 · Cited by 48
“A key potential technology is the development of integrase-defective lentiviruses that have a reduced propensity for integration into the host genome [55].”
BackgroundEefting, D., Bot, I., de Vries, M. R., Schepers, A., van Bockel, J. H., van Berkel, T. J. C., Biessen, E. A. L., & Quax, P. H. A. (2009) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2009.03.027 · Cited by 39
von Wenserski, L., Schultheiß, C., Bolz, S. N., Schliffke, S., Simnica, D., Willscher, E., Gerull, H., Wolters‐Eisfeld, G., Riecken, K., Fehse, B., et al. (2020) · Leukemia · doi:10.1038/s41375-020-01025-z · Cited by 45
In utero therapy for congenital disorders using amniotic fluid stem cells
Ramachandra, D. L., Shaw, S. W., Shangaris, P., Loukogeorgakis, S., Guillot, P. V., Coppi, P. D., & David, A. L. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00270 · Cited by 41
Retroviral E-DNA: persistence and gene expression in nondividing immune cells
Cara, A., & Klotman, M. E. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0306151 · Cited by 39
“Interestingly, a recent report showed persistence and expression from unintegrated templates in an in vivo model of gene therapy for retinal degeneration [54].”
BackgroundNeural commitment of embryonic stem cells: molecules, pathways and potential for cell therapy
Suter, D. M., & Krause, K. (2008) · The Journal of Pathology · doi:10.1002/path.2380 · Cited by 42
“Another promising approach is the use of vectors which do not integrate into the host genome and are therefore devoid of any risk of insertional mutagenesis [91].”
Kymäläinen, H., Appelt, J. U., Giordano, F. A., Davies, A. F., Ogilvie, C. M., Ahmed, S., Laufs, S., Schmidt, M., Bode, J., Yáñez‐Muñoz, R. J., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.172 · Cited by 40
“Although safer than integrating systems, vectors that exist as nuclear episomes are usually lost during repeated cell division, thus limiting gene therapy application mainly to transduction of stable postmitotic tissues (Philippe et al., 2006; Yáñez-Muñoz et al., 2006; Wanisch and YáñezMuñoz, 2009; Peluffo et al., 201…”
BackgroundMethodInfluentialSelf-citationTreating colon cancer with a suicide gene delivered by self-assembled cationic MPEG–PCL micelles
Duan, X., Wang, P., Men, K., Gao, X., Huang, M., Gou, M., Chen, L., Qian, Z., & Wei, Y. (2012) · Nanoscale · doi:10.1039/c2nr30079f · Cited by 38
Verghese, S. C., Goloviznina, N. A., Skinner, A. M., Lipps, H. J., & Kurre, P. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku082 · Cited by 37
Iyer, S. R., Yu, D., Biancotto, A., Margolis, L. B., & Wu, Y. (2009) · Journal of Virology · doi:10.1128/jvi.00874-09 · Cited by 39
“This has been recently demonstrated in studies showing that nonintegrating lentiviral vectors showed surprisingly high efficiency (equivalent to that of Wt vectors) in mediating expression from internally promoted transgenes in ocular and neuronal cells (45, 48, 64).”
SIVMAC Vpx improves the transduction of dendritic cells with nonintegrative HIV-1-derived vectors
Berger, G., Goujon, C., Darlix, J. L., & Cimarelli, A. (2008) · Gene Therapy · doi:10.1038/gt.2008.128 · Cited by 39
Distribution and fate of HIV-1 unintegrated DNA species: a comprehensive update
Hamid, F. B., Kim, J., & Shin, C. (2017) · AIDS Research and Therapy · doi:10.1186/s12981-016-0127-6 · Cited by 43
From fiction to science: clinical potentials and regulatory considerations of gene editing
Schacker, M., & Seimetz, D. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0244-7 · Cited by 39
“In recent years, non-integrative lentivirus vectors have been developed [101, 102], making lentiviruses more attractive for gene editing.”
BackgroundGenome modification in human embryonic stem cells
Tenzen, T., Zembowicz, F., & Cowan, C. A. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21948 · Cited by 44
“Integrase-defective lentiviral vectors (Leavitt et al., 1996; Naldini et al., 1996; Vargas et al., 2004; Nightingale et al., 2006; Philippe et al., 2006; Yanez-Munoz et al., 2006) provide solutions to many of these”
BackgroundCell-Based Therapy Manufacturing in Stirred Suspension Bioreactor: Thoughts for cGMP Compliance
Nath, S. C., Harper, L., & Rancourt, D. E. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.599674 · Cited by 40
Lentiviral Vectors in Cancer Immunotherapy
Oldham, R. A. A., Berinstein, E. M., & Medin, J. A. (2015) · Immunotherapy · doi:10.2217/imt.14.108 · Cited by 41
Gene transfer to the outflow tract
Dang, Y., Loewen, R. T., Parikh, H., Roy, P., & Loewen, N. A. (2016) · Experimental Eye Research · doi:10.1016/j.exer.2016.04.023 · Cited by 36
“There may be low-level expression from non-integrating, circular episomal elements that occur after cell entry (Saenz et al., 2004; Yáñez-Muñoz et al., 2006).”
BackgroundLentivirus-mediated gene transfer to the rat, ovine and human cornea
Parker, D. G., Kaufmann, C., Brereton, H. M., Anson, D. S., Francis-Staite, L., Jessup, C. F., Marshall, K., Tan, C., Koldej, R. M., Coster, D. J., et al. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302921 · Cited by 39
Román, A. J., Sl, B., Alemán, T. S., Jj, P., McDowell, J. H., Se, B., Cideciyan, A. V., Jacobson, S. G., & Hauswirth, W. (2007) · PubMed · Cited by 36
Rodríguez‐Gascón, A., del Pozo‐Rodríguez, A., Isla, A., & Solinís, M. Á. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.07.002 · Cited by 38
He, Y., Wang, M., Li, X., Yu, T., & Gao, X. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120046 · Cited by 35
Morris, G., & Schorge, S. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.03.010 · Cited by 37
Zhou, J., Li, B., Peng, C., Wang, F., Fu, Z., Zhou, C., Hong, D., Ye, F., Lü, W., & Xie, X. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.03.010 · Cited by 34
Chick, H. E., Nowrouzi, A., Fronza, R., McDonald, R. A., Kane, N. M., Alba, R., Delles, C., Sessa, W. C., Schmidt, M., Thrasher, A. J., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.042 · Cited by 35
“Equivalent ‘‘amounts’’ were used for ICLVs and IDLVs in relation to their TaqMan quantitative PCR titres.”
InfluentialSelf-citationTareen, S. U., Kelley-Clarke, B., Nicolai, C. J., Cassiano, L. A., Nelson, L. T., Slough, M. M., Vin, C. D., Odegard, J. M., Sloan, D. D., Van Hoeven, N., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2013.278 · Cited by 32
Lentiviral vectors for immunization: an inflammatory field
Pincha, M., Sundarasetty, B. S., & Stripecke, R. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.9 · Cited by 33
Gene Augmentation and Readthrough Rescue Channelopathy in an iPSC-RPE Model of Congenital Blindness
Shahi, P. K., Hermans, D., Sinha, D., Brar, S., Moulton, H. M., Stulo, S., Borys, K. D., Capowski, E. E., Pillers, D. M., Gamm, D. M., et al. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2018.12.019 · Cited by 34
Lombardo, A., Genovese, P., Beausejour, C. M., Colleoni, S., Lee, Y.-L., Kim, K. A., Ando, D. G., Urnov, F. D., Galli, C., Gregory, P. D., et al. (2008) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2007.10.064 · Cited by 33
Coutant, F., Sanchez David, R. Y., Félix, T., Boulay, A., Caleechurn, L., Souque, P., Thouvenot, C., Bourgouin, C., Beignon, A.-S., & Charneau, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048644 · Cited by 32
“Hence, transduction with NILV leads to the potent and sustained expression of the gene of interest and effective gene therapy for post-mitotic tissues such as ocular and brain tissues or liver [43,44,45,46].”
BackgroundRobertson, K. E., McDonald, R. A., Oldroyd, K. G., Nicklin, S. A., & Baker, A. H. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.002 · Cited by 31
HIV-derived vectors for therapy and vaccination against HIV
Nunzio, F. D., Félix, T., Arhel, N. J., Nisole, S., Charneau, P., & Beignon, A. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.089 · Cited by 38
“Efficient and long-term expression was reported in rodent postmitotic tissues including brain tissues [103] and with evidence of a therapeutic effect in preclinical models of retinal degeneration [104].”
Garate, Z., Davis, B. R., Bustamante, O. Q., & Segovia, J. C. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.251 · Cited by 34
“Other strategies, such as the use of nonintegrating viral vectors, are being studied, as in the case of integrationdefective lentiviral vectors (Yanez-Munoz et al., 2006; Matrai et al., 2011), but procedures to maintain nonintegrated DNA in proliferating cells have not yet been developed.”
BackgroundGene therapy for hemophilia: Progress to date and challenges moving forward
Gollomp, K. L., Doshi, B. S., & Arruda, V. R. (2019) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2019.08.012 · Cited by 33
Lentiviral Vector-Mediated RNA Silencing in the Central Nervous System
Hutson, T. H., Foster, E., Moon, L. D. F., & Yáñez‐Muñoz, R. J. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.016 · Cited by 35
Self-citationGene Therapy for the Retinal Degeneration of Usher Syndrome Caused by Mutations in MYO7A
Lopes, V. S., & Williams, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017319 · Cited by 35
“One alternative that may prove to be optimal for large genes like MYO7A is the use of nonintegrating lentiviruses; integrase-deficient vectors that can transduce retinal cells are able to persist as episomal DNA (Yáñez-Muñoz et al. 2006).”
BackgroundMeganuclease-Mediated COL7A1 Gene Correction for Recessive Dystrophic Epidermolysis Bullosa
Izmiryan, A., Danos, O., & Hovnanian, A. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2015.11.028 · Cited by 35
Integration of retroviral vectors
Gabriel, R., Schmidt, M., & Kalle, C. V. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.08.006 · Cited by 39
“Integrase defective lentiviral vectors (IDLV) have been used successfully for longterm expression of transgenes [56] or inducing RNA interference by short hairpin RNAs (shRNAs) in nondividing cells [57].”
MethodSelf-citationIntegrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity
Negri, D. R., Michelini, Z., Bona, R., Blasi, M., Filati, P., Leone, P., Rossi, A., Franco, M., & Cara, A. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.571670 · Cited by 31
“Importantly, recent reports have shown that in vivo-delivered IDLV persist in a model animal for up to one year from the inoculum in non dividing cells or tissues [43-48].”
BackgroundMethodNon-viral episomal modification of cells using S/MAR elements
Argyros, O., Wong, S., & Harbottle, R. P. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.582035 · Cited by 34
“Non -integrating lentivirus Efficient and sustained expression in a broad range of tissues Loss of expression in dividing cells Risk of insertional mutagenesis [79]”
BackgroundRetinal Degeneration Progression Changes Lentiviral Vector Cell Targeting in the Retina
Calame, M., Cachafeiro, M., Philippe, S., Schouwey, K., Tekaya, M., Wanner, D., Sarkis, C., Kostic, C., & Arsenijevic, Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023782 · Cited by 29
“AAV-based gene therapy has shown many successes in gene replacement treatments for animal models of autosomal inherited retinal degeneration[8], whereas the HIV1-derived lentiviral vectors (LVs) were efficient against diseases affecting the RPE[1,9–11], in retinal ganglion cells when injured[12], and in photoreceptors…”
BackgroundCell and Gene Therapy for HIV Cure
Peterson, C. W., & Kiem, H. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_71 · Cited by 37
Gene therapy of inherited immunodeficiencies
Santilli, G., Thornhill, S. I., Kinnon, C., & Thrasher, A. J. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.4.397 · Cited by 31
Self-citationRegulation of Episomal Gene Expression by KRAB/KAP1-Mediated Histone Modifications
Barde, I., Laurenti, E., Verp, S., Groner, A. C., Towne, C. L., Padrun, V., Aebischer, P., Trumpp, A., & Trono, D. (2009) · Journal of Virology · doi:10.1128/jvi.00001-09 · Cited by 32
“Previous studies demonstrated that IDLV are competent for delivering transgenes to the nuclei of target cells, where they are expressed in the absence of integration (22, 24, 33).”
Background
Metadata
- Authors
- Yáñez-Muñoz, R. J., Balaggan, K. S., MacNeil, A., Howe, S. J., Schmidt, M., Smith, A. J., Buch, P., MacLaren, R. E., Anderson, P. N., Barker, S. E., Duran, Y., Bartholomae, C., von Kalle, C., Heckenlively, J. R., Kinnon, C., Ali, R. R., & Thrasher, A. J.
- Affiliations
- University College London (GB)
- University of Freiburg (DE)
- Great Ormond Street Hospital (GB)
- Corresponding author
- Ali, Robin R
- ORCID
- Venue
- Nature Medicine
- Published
- 2006-02-19
- Volume
- 12
- Issue
- 3
- Pages
- 348-353
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2167845957
- Cited by
- 460
- References
- 30
- Citations by year
- 2026: 4 · 2025: 18 · 2024: 8 · 2023: 10 · 2022: 14 · 2021: 14 · 2020: 13 · 2019: 19 · 2018: 11 · 2017: 21 · 2016: 19 · 2015: 24 · 2014: 31 · 2013: 27 · 2012: 35
- FWCI
- 21.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Wellcome Trust
- University College London
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- insertional mutagenesis, retroviral vectors, stable transgene expression, ocular gene therapy, retinal degeneration, postmitotic tissues
- MeSH terms
- Retinoid Isomerohydrolase, Animals, Brain, Carrier Proteins, Electroretinography, Eye Proteins, Female, Genetic Vectors, HeLa Cells, Humans, Pigment Epithelium of Eye, Retina, Tumor Cells, Cultured, Genetic Therapy, Lentivirus, Virus Integration, cis-trans-Isomerases, Green Fluorescent Proteins, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.